Systematic review on fecal calprotectin in cystic fibrosis

J Pediatr (Rio J). 2023 Jan-Feb;99(1):4-10. doi: 10.1016/j.jped.2022.01.006. Epub 2022 May 3.

Abstract

Objectives: Fecal calprotectin is an inflammatory marker used for monitoring intestinal diseases. It has been studied as a marker of intestinal inflammation in cystic fibrosis (CF), a multi-systemic genetic disease caused by alterations to the CFTR gene. Manifestations of the disease favor a systemic inflammation not limited to the respiratory tract, therefore, calprotectin is a non-invasive and effective diagnostic method. The aim of the study was to perform a systematic review of the literature with a qualitative synthesis of studies.

Sources: The articles were selected from PubMed, Web of Science, Scielo and Lilacs.

Summary of the findings: Nine studies were selected for that qualitative synthesis, one was a randomized clinical trial, and eight were case-control or cohort designs. Most studies have indicated that calprotectin is a marker of systemic inflammation in CF and not just intestinal inflammation. Calprotectin is an aid in monitoring inflammatory bowel conditions in patients with cystic fibrosis.

Conclusion: Further studies should be conducted to investigate the role of this marker in the systemic inflammation of CF.

Keywords: Biomarkers; Calprotectin; Cystic fibrosis; Inflammation; Systematic review.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Biomarkers
  • Cystic Fibrosis* / diagnosis
  • Feces
  • Humans
  • Inflammation
  • Intestines
  • Leukocyte L1 Antigen Complex
  • Randomized Controlled Trials as Topic

Substances

  • Leukocyte L1 Antigen Complex
  • Biomarkers